Luspatercept,

Luspatercept,

Form: Lyophilized powder for subcutaneous injection

Strength: 25 mg, 75 mg

Reference Brands: Reblozyl

Category: Anemia

Luspatercept is a groundbreaking erythroid maturation agent used to treat anemia in patients with beta thalassemia and myelodysplastic syndromes (MDS). Marketed under the brand name Reblozyl, it is approved by the FDA and EMA for reducing red blood cell transfusion dependence. Luspatercept is a recombinant fusion protein administered via subcutaneous injection and produced under strict GMP compliance. Ideal for pharmaceutical distributors, wholesalers, and B2B partners seeking high-demand biologics. We offer global bulk supply, regulatory support, and competitive pricing for Luspatercept. Partner with us for reliable sourcing and efficient delivery. Contact us now for Luspatercept export and distribution solutions.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Deferoxamine

Strength: 500 mg/vial, 2 g/vial

Form: Lyophilized powder for injection

Reference Brands: Desferal

View Details Get Enquiry
Deferasirox

Strength: 125 mg, 250 mg, 500 mg

Form: Tablets for Oral Suspension

Reference Brands: Exjade, Jadenu (film-coated)

View Details Get Enquiry
Iron(III)-Isomaltoside Injection

Strength: 100mg/ml

Form: Injection

Reference Brands: Monofer,, Diafer, Monoferric

View Details Get Enquiry
Iron Dextran

Strength: 50 mg/mL

Form: injection

Reference Brands: Dexferrum,INFeD

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.